Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPAC1: Adjuvant Chemotherapy for Stage II Colon Cancer
NCT03199989Phase 3Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2017
- Primary completion
- Jul 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in colon cancer, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03199989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199989.